Similar Search Results

The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003-2013

Lichtenberg, Frank R. - In: Latin American economic review : LAER ; official … 26 (2017), pp. 1-22

I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003–2013, by ….) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate … the standards of the World Health Organization, new cancer drugs have been very cost-effective in Mexico. The contribution …

Persistent link: https://www.econbiz.de/10011885726

Corporate Social Responsibility (CSR) of innovative pharmaceutical corporations : the case of BIOGEN

Witkowska, Janina - In: Comparative economic research : Central and Eastern Europe 21 (2018) 3, pp. 45-62

between the economic and social/ethical aspects of innovation processes in this field. A key issue of CSR in the innovative …

Persistent link: https://www.econbiz.de/10011960021

International research networks in pharmaceuticals : structure and dynamics

Cantner, Uwe; Rake, Bastian - In: Research policy : policy, management and economic … 43 (2014) 2, pp. 333-348

Persistent link: https://www.econbiz.de/10010407472

The revolution re-visited : clinical and genetics research paradigms and the productivity paradox in drug discovery

Gittelman, Michelle - In: Research policy : policy, management and economic … 45 (2016) 8, pp. 1570-1585

Persistent link: https://www.econbiz.de/10011599152

Financing vaccines for global health security

Vu, Jonathan T.; Kaplan, Benjamin K.; Chaudhuri, Shomesh; … - In: Journal of investment management : JOIM 20 (2022) 2, pp. 51-67

Persistent link: https://www.econbiz.de/10013433610

Ensuring quality science from "R" to "D" : an optimal adoption strategy for in-licensing of pharmaceutical innovation

Zhao, Guozhen; Chen, Wenhong - In: IEEE transactions on engineering management : EM 58 (2011) 4, pp. 643-661

Persistent link: https://www.econbiz.de/10009388864

Big Pharma, little science? : a bibliometric perspective on Big Pharma's R&D decline

Rafols, Ismael; Hopkins, Michael M.; Hoekman, Jarno; … - In: Technological forecasting & social change : an … 81 (2014), pp. 22-38

Persistent link: https://www.econbiz.de/10010403289

Rushed innovation : evidence from drug licensing

Hermosilla, Manuel - In: Management science : journal of the Institute for … 67 (2021) 1, pp. 257-278

Persistent link: https://www.econbiz.de/10012435267

The role of Information Technology and employee engagement in enhancing Knowledge Management in the pharmaceutical Research and Development process : insights from dynamic capabilities theory

Chatzifoti, Natalia; Didaskalou, Eleni A.; Chountalas, … - In: Businesses 4 (2024) 3, pp. 315-330

This study investigates the impact of Information Technology and employee engagement on the implementation of Knowledge Management within the Research and Development processes of pharmaceutical companies. Based on Dynamic Capabilities Theory, this research examines the interaction between these...

Persistent link: https://www.econbiz.de/10015098513

One lab, two firms, many possibilities : on R&D outsourcing in the biopharmaceutical industry

Billette de Villemeur, Étienne; Versaevel, Bruno - In: Journal of health economics 65 (2019), pp. 260-283

Persistent link: https://www.econbiz.de/10012224616